Apixaban Dosing for a 16 kg Child with Proximal DVT
For a 16 kg child with proximal deep vein thrombosis, apixaban should be dosed at 140 mg twice daily based on the most recent 2025 ASH/ISTH pediatric VTE guidelines. 1
Recommended Dosing Regimen
The 2025 American Society of Hematology/International Society on Thrombosis and Haemostasis guidelines provide specific weight-based dosing for apixaban in pediatric patients 1:
- For children weighing 16 to <21 kg and aged 12 to <24 months: 140 mg twice daily
This dosing is derived from pediatric pharmacokinetic studies that established weight-tiered fixed doses targeting appropriate therapeutic exposures in children 2, 3.
Important Clinical Considerations
Why Not Standard Adult Dosing
The FDA-approved adult dosing for DVT treatment (10 mg twice daily for 7 days, then 5 mg twice daily) 4 cannot be directly applied to pediatric patients because:
- Children have significantly different pharmacokinetics, with 52.4% lower absorption rates and 43.1% lower central volume of distribution compared to adults 3
- Age-dependent maturation affects drug clearance, particularly in children under 9 months 2
- Weight-based dosing is essential to achieve target therapeutic exposures
Alternative if Apixaban Unavailable
If apixaban is not accessible, the 2025 guidelines recommend low-molecular-weight heparin as first-line therapy 1:
- Enoxaparin: 1 mg/kg subcutaneously every 12 hours (for children >5 years)
- Target peak anti-FXa level: 0.5-1.0 IU/mL, checked 4 hours after the second or third dose
- Dose adjustments per nomogram based on anti-FXa levels 1
Critical Safety Points
Apixaban use in pediatric DVT requires careful consideration:
Limited pediatric data: While the 2025 guidelines provide dosing recommendations, the 2018 ASH guidelines explicitly stated that direct oral anticoagulants should only be used within formal clinical trials 5. The updated 2025 guidelines now include specific dosing based on completed pediatric studies.
Bleeding risk: The PREVAPIX-ALL trial showed increased clinically relevant non-major bleeding (primarily epistaxis) in younger children receiving apixaban 6, though major bleeding rates were similar to standard of care.
Monitoring: Unlike LMWH, apixaban does not require routine laboratory monitoring, but clinical assessment for bleeding and thrombosis recurrence is essential.
Treatment Duration
For acute proximal DVT in children, anticoagulation should continue for at least 3 months, with duration individualized based on:
- Presence of ongoing risk factors (e.g., central venous catheter)
- Thrombus burden and location
- Underlying thrombophilia
Practical Administration
For a 16 kg child requiring 140 mg twice daily:
- Use apixaban oral solution (0.4 mg/mL) or tablets as available
- Administer every 12 hours with or without food
- If a dose is missed, give as soon as possible on the same day; do not double dose 4
The strong recommendation for anticoagulation in symptomatic pediatric DVT is based on extrapolation from adult data and the potentially life-threatening nature of untreated VTE in hospitalized children 5, despite the overall low certainty of direct pediatric evidence.